This study evaluated the performance of the Rapidec Carba NP test, which was introduced recently into the market for the detection of carbapenemase production in a broad spectrum of ␤-lactamase-producing Enterobacteriaceae clinical isolates. In total, 252 clinical Enterobacteriaceae isolates that had been genetically characterized with respect to carbapenemase, extended-spectrum ␤-lactamase (ESBL), and AmpC genes were analyzed; 51/252 isolates (20.2%) were genetically confirmed to be carbapenemase producers, whereas 201/252 isolates (79.8%) were genetically negative for the presence of carbapenemase genes. The Rapidec Carba NP test was applied according to the manufacturer's instructions, and results were read after 30 and 120 min of incubation. The overall sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the Rapidec Carba NP test were 90.2%, 100%, 100%, and 97.6%, respectively, when the manufacturer's instructions were followed. Four of 5 false-negative results occurred with OXA-48-like enzymes. After an incubation time of 30 min, the sensitivity was 49%. The sensitivity increased to 100% when the recommended bacterial inoculum was doubled and the test was read strictly after 120 min of incubation. The Rapidec Carba NP test is a useful tool for the reliable confirmation of carbapenemase-producing Enterobacteriaceae isolates. The test should be read strictly after 120 min of incubation and the inoculum should be larger than recommended by the manufacturer.
I
n recent years, the emergence of diverse carbapenemases in Enterobacteriaceae has become a major challenge for health care systems (1) . Treatment options for carbapenemase producers are alarmingly limited, and often drugs that display significant side effects need to be administered as a last resort (2) .
Carbapenemases were classified according to their functional properties and molecular structure by Ambler and Bush, e.g., Klebsiella pneumoniae carbapenemase (KPC) (Ambler class A/Bush group 2f), New Delhi metallo-␤-lactamase (NDM)-, VIM-, and GIM-type enzymes (all Ambler class B/Bush group 3), or OXA-48 (Ambler class D/Bush group 2d) (3, 32) . In recent years, KPC enzymes have become endemic in North America, Italy, Greece, Poland, and Great Britain (4); NDM hotspots are located in India, Bangladesh, and Pakistan. In Europe, NDM is most frequently encountered in Great Britain (5) . OXA-48, which was originally observed in Turkey, is being observed in many European countries with alarmingly increased frequency (6) . Rapid, easy-to-use, practical laboratory tests are needed for early detection, to provide the basis for limiting the spread of carbapenemases through hospital measures for isolation of patients carrying carbapenemase-producing Enterobacteriaceae strains.
A continuously increasing number of tests have been described for carbapenemase detection, including commercially available or laboratory-developed tests based on phenotypic or molecular methods (7) (8) (9) . Critical diameters or MICs for meropenem were recommended by EUCAST for carbapenemase screening and have been demonstrated to be highly sensitive (10, 11) . To confirm the production of carbapenemases, the CLSI recommends the modified Hodge test and the Carba NP I test (12) . Alternatively, several commercially available and laboratory-developed combined disk tests that use boronic acid and EDTA/dipicolinic acid as specific carbapenemase inhibitors are available (11, (13) (14) (15) (16) . In its 2013 guidelines for the detection of carbapenemases, EUCAST recommended combined disk tests for carbapenemase confirmation (10). Nordmann and coworkers described a new inhibitor-based biochemical assay for carbapenemase detection, the Carba NP test, which has been developed in two versions; the Carba NP-I assay provides a positive or negative result (carbapenemase detected or not detected), whereas the Carba NP-II test is designed to discriminate among carbapenemase classes A, B, and D (17, 18) . Two commercially available tests use the principle of imipenem hydrolysis and a colorimetric pH indicator to detect the presence of carbapenemases, i.e., the Rapid Carb Screen kit (Rosco Diagnostica, Taastrup, Denmark) and the Rapidec Carba NP test, which was derived from the Carba NP-I assay and was introduced recently into the market (19, 20) . The Rapid Carb Screen kit contains three separate vials, whereas the Rapidec Carba NP is performed on one plastic strip with preformed wells, which limits handling and minimizes the potential for confusion of the vials. This study aimed at evaluating the performance of the Rapidec Carba NP test with a broad set of ␤-lactamase-producing Enterobacteriaceae clinical isolates.
MATERIALS AND METHODS
Bacterial isolates. In total, 252 nonduplicate clinical isolates that had been recovered in our laboratory between 2009 and 2015 were included in the study (Table 1 ). All isolates had been previously characterized phenotypically and genetically for the presence of extended-spectrum ␤-lactamases (ESBLs) (TEM, SHV, and CTX-M types), plasmid-encoded AmpCs, chromosomal ampC promoter/attenuator mutations leading to overexpression (Escherichia coli only), and carbapenemases (8, 21, 22) . Genetic detection of carbapenemase, ESBL, and ampC genes. After growth on sheep blood agar, total DNA was extracted from bacterial colonies using the InstaGene matrix (Bio-Rad, Reinach, Switzerland). Genetic detection of carbapenemase genes was performed with a multiplex PCR assay for the following 11 genes: bla IMP , bla VIM , bla NDM , bla SPM , bla AIM , bla DIM , bla GIM , bla SIM , bla KPC , bla BIC , and bla OXA-48 (8) . For variant analysis, bla OXA-48 genes were amplified with the primers described (23) . PCR amplicons were sequenced using PCR primers, and sequences were analyzed using GenBank and DNASTAR Lasergene software (DNASTAR Inc., Madison, WI). The AID ESBL line probe assay (Autoimmun Diagnostika GmbH, Germany) was used for detection of ESBL genes (24) . Bacterial isolates were genetically characterized for the presence of plasmid-mediated AmpC-type ␤-lactamase genes with a multiplex PCR assay (25) . Chromosomal ampC promoter mutations of E. coli isolates were analyzed as described previously (26) . Fifty-one (20.2%) of 252 isolates were genetically confirmed to be carbapenemase producers and formed the study group. The negative-control group (n ϭ 201) included 152/252 isolates (60.3%) with suspected carbapenemase production (according to the EUCAST screening cutoff value of Ͻ25 mm for the meropenem inhibition zone) that were genetically negative for carbapenemase genes and 49/252 isolates (19.4%) without phenotypically suspected carbapenemase production (meropenem inhibition zone of Ն25 mm) that were genetically negative for AmpC, ESBL, and carbapenemase genes.
Susceptibility testing. Disk diffusion susceptibility testing was performed according to EUCAST recommendations (27) . Antibiotic disks and Mueller-Hinton agar were obtained from Becton Dickinson (Franklin Lakes, NJ). Zone diameters were recorded using the Sirweb/Sirscan system (i2a, Montpellier, France). MICs were determined by gradient diffusion (Etest; bioMérieux, Marcy l'Etoile, France), according to the manufacturer's instructions.
Rapidec Carba NP testing. The Rapidec Carba NP test was performed according to the manufacturer's instructions. The inoculum was prepared by comparison with the provided turbidity standard, using a loopful of colony material. The test was repeated for carbapenemase-positive isolates with false-negative results by applying the following modification: the inoculum was increased by preparing the inoculum in comparison with the provided turbidity standard and then adding additional colony material by using the picking tool and the visual guide provided by the manufacturer, i.e., the same amount of colony material needed to prepare the manufacturer-recommended McFarland standard doubling the total inoculum. Reactions were read after 30 and 120 min of incubation. Color changes from red to yellow-orange were interpreted as follows: any color change from red to yellow-orange was rated as a positive test result, irrespective of the yellow-orange color intensity. The reading guide provided by the manufacturer was used to ensure correct interpretation. The test was performed by experienced personnel, and all discrepant results were repeated.
Software. All calculations were performed using IBM SPSS version 20 statistics software (IBM Corp., Armonk, NY) and Microsoft Excel 2010 software (Microsoft Corp., Redmond, WA). Rapidec Carba NP testing according to manufacturer's instructions. The overall sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the Rapidec Carba NP test after 120 min of incubation were 90.2%, 100%, 100%, and 97.6%, respectively, when the manufacturer's instructions were followed. Four of 5 false-negative results occurred with OXA-48-like enzymes, in one Citrobacter koseri isolate, two E. coli isolates, and one K. pneumoniae isolate; one false-negative result was obtained with a VIM-type enzyme. After an incubation time of 30 min, the sensitivity was 49%, i.e., 27/51 carbapenemase producers tested negative. Nineteen (70%) of 27 isolates with negative readings after 30 min of incubation harbored OXA-48-like enzymes, four (15%) harbored VIM enzymes, three (11%) harbored 
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a Both chromosomally encoded and plasmid-encoded ampC. b All carbapenemase-producing strains displayed meropenem inhibition zones of Ͻ25 mm; KPC-producing strains showed meropenem zones ranging from 6 to 23 mm (mean, 14 mm), NDM-producing strains showed meropenem zones ranging from 6 to 22 mm (mean, 14 mm), VIM-producing strains showed meropenem zones ranging from 6 to 21 mm (mean, 14 mm), IMI-, GIM-, and IMP-producing strains showed meropenem zones of 14 mm, 19 mm, and 21 mm, respectively, and OXA-48-producing strains showed meropenem zones ranging from 6 to 24 mm (mean, 16 mm).
NDM enzymes, and one harbored a KPC enzyme. Twenty-two of the 27 isolates with negative readings after 30 min of incubation yielded positive test results after 120 min of incubation. No fading of the color reaction was seen after 120 min for tests that were already positive after 30 min of incubation. Rapidec Carba NP testing modified with larger inoculum. The sensitivity increased to 100% when the bacterial inoculum was doubled and the test was read strictly after 120 min of incubation. Twenty-two isolates that yielded negative results after 30 min of incubation became positive after 120 min, including 15 OXA-48-producing isolates (11 K. pneumoniae, 3 E. coli, and 1 Enterobacter aerogenes), 1 KPC-producing K. pneumoniae isolate, 3 NDM-producing isolates (2 Providencia rettgeri and 1 Proteus mirabilis), and 3 isolates producing VIM-type enzymes (2 Enterobacter cloacae and 1 Citrobacter freundii).
DISCUSSION
Commercially available tests have several advantages over laboratory-developed assays, i.e., production is highly standardized and the quality is controlled by the manufacturer, reagents are preprepared and ready to use, and the shelf-life of the test kits is guaranteed. In the present study, the Rapidec Carba NP test performed according to the manufacturer's protocol (including the recommended turbidity standard for the bacterial inoculum) showed an overall sensitivity of 90.2% and a NPV of 97.6% (Table 2 ). The sensitivity in the present study was slightly lower than that reported in a recent study by the inventors of the Carba NP test, which found both the sensitivity and the specificity of the Rapidec Carba NP test to be 96% (19) . The difference in sensitivity may be attributable to the different study populations, i.e., 20% (51/252 isolates) carbapenemase producers in the present study population versus 56% (98/173 isolates) in the study by Poirel and Nordmann (19) . The Rapidec Carba NP test seems to provide greater sensitivity than the original "homemade" Carba NP I test, which was reported to display sensitivities of 72.5% to 100%, depending on the modification to the original protocol (11, 28, 29) . The results of this study confirm previously reported findings pointing to ambiguities in the reading of the Carba NP II test for bla OXA-48 -positive isolates frequently producing false-negative results, as four of five false-negative results occurred with OXA-48-like enzymes (11) . The CLSI has indicated this restriction for the Carba NP test in the most recent guidelines (12) . However, when the recommended inoculum for the Rapidec Carba NP test (one loop, i.e., 10 l of colony material) was increased by adding an additional loop of colony material and reading was performed strictly after 120 min of incubation (modification made according to personal communication with P. Nordmann), the sensitivity increased to 100%. Whether an increased inoculum will decrease the specificity of the test, e.g., for isolates that are not susceptible to carbapenems due to AmpC overexpression and related carbapenem hydrolysis in combination with porin deficiency, is a concern that could not be investigated further in this study (30) . Reading the test after 30 min of incubation showed low sensitivity (49% overall), particularly for OXA-48-like enzymes; none of the 19 isolates tested yielded a positive result after 30 min of incubation. Therefore, it is of critical importance to read the test after a minimum of 120 min in epidemiological settings with a high prevalence of OXA-48-like enzymes.
False-negative Carba NP results were reported previously, e.g., for Providencia rettgeri, Providencia stuartii, or Proteus mirabilis, in particular for mucoid isolates and isolates with NDM enzymes (11, 29, 31) . Negative results were linked to variations in protein extraction, to species-specific characteristics, or to the agar type and ion content used for cultivation of the isolates in question. Of note, three NDM-producing isolates of Providencia rettgeri, Providencia stuartii, and Proteus mirabilis that displayed false-negative test results with the Carba NP-II test in a previous study were found to be positive using the Rapidec Carba NP test after 120 min of incubation, using the manufacturer-recommended inoculum. The test results were read as negative after 30 min of incubation, whereas all other bla NDM -positive isolates (six K. pneumoniae and one Citrobacter freundii) showed positive results after 30 min of incubation. Thus, it is of critical importance to read the Rapidec Carba NP test results for P. rettgeri, P. stuartii, and P. mirabilis after a minimum of 120 min.
A limitation of this study was the relatively small number of carbapenemase types that are encountered more rarely in our epidemiological setting, e.g., GIM, IMI, and VIM. Furthermore, it would be of interest to determine how the Rapidec Carba NP test performs for non-glucose-fermenting Gramnegative rods.
In summary, the Rapidec Carba NP test was demonstrated to be a useful tool for the reliable confirmation of carbapenemaseproducing Enterobacteriaceae isolates. The test should be read strictly after 120 min of incubation, particularly in cases in which a The test was repeated only for carbapenemase-positive isolates with false-negative results using the manufacturer-recommended preparation.
bla OXA-48 is suspected and cases involving P. rettgeri, P. stuartii, and P. mirabilis isolates. In addition, the inoculum should be larger than recommended by the manufacturer.
